{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:42:03Z","timestamp":1774989723312,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.metabol.2012.08.021","type":"journal-article","created":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T04:59:19Z","timestamp":1348635559000},"page":"S34-S39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S1","title":["Personalized medicine in major depressive disorder \u2014 Opportunities and pitfalls"],"prefix":"10.1016","volume":"62","author":[{"given":"Diane B.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"O'Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2012.08.021_bb0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/07853890600551045","article-title":"Pharmacogenomics and antidepressant drugs","volume":"38","author":"Binder","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.metabol.2012.08.021_bb0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.pra.0000405364.90043.bd","article-title":"A primary care focus on the diagnosis and treatment of major depressive disorder in adults","volume":"17","author":"Halaris","year":"2011","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.metabol.2012.08.021_bb0015","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852912000375","article-title":"Clinical and pharmacologic perspectives on the treatment of major depressive disorder","volume":"16","author":"Jefferson","year":"2011","journal-title":"CNS Spectr"},{"key":"10.1016\/j.metabol.2012.08.021_bb0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1370\/afm.641","article-title":"Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis","volume":"5","author":"Gaynes","year":"2007","journal-title":"Ann Fam Med"},{"issue":"7 Suppl","key":"10.1016\/j.metabol.2012.08.021_bb0025","first-page":"3.6","article-title":"Major depression is sometimes described as the common cold of psychiatry","volume":"22","author":"Goodwin","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.metabol.2012.08.021_bb0030","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/sj.npp.1301131","article-title":"Report by the ACNP Task Force on response and remission in major depressive disorder","volume":"31","author":"Rush","year":"2006","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.metabol.2012.08.021_bb0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11920-010-0160-4","article-title":"Biomarkers to predict antidepressant response","volume":"12","author":"Leuchter","year":"2010","journal-title":"Curr Psychiatry Rep"},{"issue":"Suppl 2","key":"10.1016\/j.metabol.2012.08.021_bb0040","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1007\/s00406-010-0152-8","article-title":"Is there personalized medicine for mood disorders?","volume":"260","author":"Bartova","year":"2010","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.metabol.2012.08.021_bb0045","series-title":"Diagnostic and statistical manual of mental disorders, 4th ed, text revision","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.metabol.2012.08.021_bb0050","series-title":"Practice guideline for the treatment of patients with major depressive disorder","first-page":"17","author":"Psychiatric Association","year":"2010"},{"key":"10.1016\/j.metabol.2012.08.021_bb0055","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/npp.2011.151","article-title":"Functional biomarkers of depression: diagnosis, treatment, and pathophysiology","volume":"36","author":"Schmidt","year":"2011","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.metabol.2012.08.021_bb0060","author":"Natnl Institute for Clinical Excellence (NICE)"},{"key":"10.1016\/j.metabol.2012.08.021_bb0065","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/bmj.330.7495.800","article-title":"Managing depression in primary care","volume":"330","author":"Tyle","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2012.08.021_bb0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpsychores.2009.05.003","article-title":"Assessment of mood guides for clinicians","volume":"68","author":"Furukawa","year":"2010","journal-title":"J Psychosom Res"},{"issue":"Suppl 8","key":"10.1016\/j.metabol.2012.08.021_bb0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4088\/JCP.8133su1c.04","article-title":"Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission","volume":"70","author":"Trivedi","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.021_bb0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0033291703001107","volume":"34","author":"Trivedi","year":"2004","journal-title":"Psychol Med"},{"key":"10.1016\/j.metabol.2012.08.021_bb0085","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s11920-008-0074-6","article-title":"Chronic depression: update on classification and treatment","volume":"10","author":"Torpey","year":"2008","journal-title":"Cur Psychiatry Rep"},{"key":"10.1016\/j.metabol.2012.08.021_bb0090","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4088\/JCP.10m06168blu","article-title":"Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care","volume":"71","author":"Kuk","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.021_bb0095","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1176\/appi.ajp.2010.09111680","article-title":"Personalized medicine for depression: can we match patients with treatments?","volume":"167","author":"Simon","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.021_bb0100","article-title":"A practical approach to the early identification of antidepressant medication non-responders","author":"Li","year":"2011","journal-title":"Psychological Med"},{"key":"10.1016\/j.metabol.2012.08.021_bb0105","first-page":"89","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2012.08.021_bb0110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11920-011-0232-0","article-title":"Is depression an inflammatory disorder?","volume":"13","author":"Raison","year":"2011","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.metabol.2012.08.021_bb0115","doi-asserted-by":"crossref","unstructured":"Stetler C, Miller GE. Depression and hypothalamic\u2013pituitary\u2013adrenal activation: a quantitative summary of four decades of research. 2011;73:114\u201326.","DOI":"10.1097\/PSY.0b013e31820ad12b"},{"key":"10.1016\/j.metabol.2012.08.021_bb0120","article-title":"Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study","author":"Papakostas","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.021_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1586\/ern.10.186","article-title":"Pharmacogenetics of antidepressant response","volume":"11","author":"Keers","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.metabol.2012.08.021_bb0130","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.324_1628","article-title":"Depression gene. Back to the drawing board for psychiatric genetics.","volume":"324","author":"Holden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.metabol.2012.08.021_bb0135","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/YCO.0b013e32833f0e3a","article-title":"Current developments and controversies: does the serotonin transport gene-linked polymorphic region (5-HTTLPR) modulate the association between stress and depression?","volume":"23","author":"Wankerl","year":"2010","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.021_bb0140","doi-asserted-by":"crossref","first-page":"435","DOI":"10.31887\/DCNS.2009.11.4\/afleuchter","article-title":"A new paradigm for the prediction of antidepressant treatment response","volume":"11","author":"Leuchter","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.metabol.2012.08.021_bb0145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/479278a","article-title":"Depression drug disappoints.","volume":"479","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2012.08.021_bb0150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/11593960-000000000-00000","article-title":"A benefit\u2013risk assessment of agomelatine in the treatment of major depression","volume":"34","author":"Howland","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.metabol.2012.08.021_bb0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pnpbp.2011.08.013","article-title":"Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries","volume":"36","author":"Olgiati","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.021_bb0160","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/clpt.2011.172","article-title":"Pharmacogenetics: call to action","volume":"90","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2012.08.021_bb0165","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/15622975.2011.572998","article-title":"A model to incorporate genetic testing (5HTTLPR) in pharmacological treatment of MDD","volume":"12","author":"Serretti","year":"2011","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.021_bb0170","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/138161210790112728","article-title":"Pharmacogenetics in psychiatry \u2014 a useful clinical tool or wishful thinking for the future?","volume":"16","author":"Kirchheiner","year":"2010","journal-title":"Curr. Pharmaceutical Design"},{"key":"10.1016\/j.metabol.2012.08.021_bb0175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cll.2008.05.006","article-title":"Pharmacogenetics-guided dose modification of antidepressants","volume":"28","author":"Seeringer","year":"2008","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.metabol.2012.08.021_bb0180","first-page":"06","article-title":"The ghost of personalized medicine","author":"Grant","year":"2011","journal-title":"The Scientist"},{"key":"10.1016\/j.metabol.2012.08.021_bb0185","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.pnpbp.2010.11.031","article-title":"Genome-wide association studies of antidepressant outcome: a brief review","volume":"35","author":"Laje","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.021_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00129785-200303060-00002","article-title":"Pharmacogenomics and \u201cindividualized drug therapy:High expectations and disappointing achievements","volume":"3","author":"Nebert","year":"2003","journal-title":"Am J Pharmacogenomics"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:57:30Z","timestamp":1758427050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049512003253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":38,"alternative-id":["S0026049512003253"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2012.08.021","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized medicine in major depressive disorder \u2014 Opportunities and pitfalls","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2012.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}